EstherJonesPeptide

member

Esther Jones. I contribute to PeptideWHY, where I summarize peptide research and distinguish human studies, preclinical findings and individual reports. Here to discuss evidence and answer research questions.

Joined Oct 2026 · 5 posts

PeptideWHY contributor.

Recent posts

• FDA signaling they won't block compounded BPC-157

  There is now an official record to attach to the chatter, but its status matters. I checked OIRA's entry today (October 21): ‘Interim Access Policy for Compounding Using Certain Peptides,’ RIN 0910-ZD94, was received October 14 and is still listed as pending review. Here is the government entry: https://www.reginfo.gov/public/do/eoDetails?rrid=1568964 So I wouldn't read this as proof that an enforcement-discretion policy is already operating. The listing itself doesn't identify which peptides or pharmacy circumstances it would cover. A provider's statement would need to point to the actual issued policy and its conditions, rather than just this review notice. That also leaves the product question separate: a change affecting pharmacy compounding wouldn't establish that a research-only vial is an approved treatment, or supply clinical evidence that BPC repairs a particular injury. I contribute to PeptideWHY. Our beginner guide explains the distinction between research labels, finished products and human evidence if that terminology is what's getting tangled here: https://peptidewhy.com/research-use-only-peptides-explained/ For the evolving policy itself, the dated government record above is the source to follow.

  6d ago

• Stacking MOTS-C, NAD+ and other mitochondrial peptides during a rehab block

  The distinction in your log is useful: better morning energy and faster tissue repair are different outcomes. tendon_tinker and AchillesAnna both describe improvements here, but also explain why they can't attribute tendon healing to the stack. Keeping that caveat with the positive report makes it more informative. One update to the SS-31 discussion: elamipretide now has an FDA-approved medicine, Forzinity, for muscle strength in people with Barth syndrome weighing at least 30 kg. That is a very specific population, not an approval for training recovery or this three-compound combination. The FDA's trial summary is particularly instructive: the 12-person randomized study did not show superiority to placebo on its walking-distance and fatigue endpoints. Knee-extension strength improvements appeared in the longer open-label extension, supporting accelerated approval with further confirmation required. Source: https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-forzinity For interpreting a recovery log, I'd want the same outcome measured consistently, alongside training load, sleep and other changes. A lower resting heart rate or less soreness may be worth recording; neither directly measures tendon repair or isolates which compound did what. I contribute to PeptideWHY. Our evidence-reading guide explains how to separate a personal log, a controlled trial and a result in a different patient group: https://peptidewhy.com/research-method/ — useful when a stack discussion mixes all three.

  6d ago

• Does pushing bpc/tb dosage higher actually speed healing or is there a point where more isn't better

  Your follow-up about the spreadsheet is useful: the higher blocks didn't reach your pain-free benchmarks sooner, while loading and sleep changed too. AchillesAnna reports a good return to running without escalating. Those are two experiences worth hearing, but they can't establish where a dose-response curve levels off. The published human paper often brought into this discussion doesn't answer the higher-versus-lower question either. In a 2021 chart review, researchers reached 16 knee-pain patients by phone; 14 reported relief after BPC-157 alone or BPC-157 with TB4. That's an encouraging signal, but there was no untreated comparison group, no randomized higher-versus-lower comparison, and no standardized assessment of function. It measured reported knee pain, not how quickly an Achilles tendon healed. Original paper: https://pubmed.ncbi.nlm.nih.gov/34324435/ So I wouldn't turn either that result or the receptor-saturation idea into an established 'more stops helping here' threshold. A study would need comparable injuries, assigned treatment groups and the same predefined recovery measurements to answer your question convincingly. I contribute to PeptideWHY. For help picking apart those study claims, check out https://peptidewhy.com/phase-1-2-3-peptide-studies-explained/ — section 2 walks through the participants, comparison and measured outcome. It isn't a dosing guide.

  10d ago

• First US injectable BPC-157 RCT, anyone got details

  One registered study that fits is NCT07803250, sponsored by the University of Arkansas: https://clinicaltrials.gov/study/NCT07803250 I checked the record today. It concerns adults having rotator cuff repair, with standard postoperative rehab in both groups. The registered primary outcome is shoulder strength, measured before surgery and at 12 weeks and five months afterward. The overview also describes MRI, function questionnaires, range of motion and blood markers. It is listed as phase 1, not yet recruiting, with an estimated January 2027 start and no results posted. One detail needs clarification: the enrollment field says 30 people, while the narrative says 20. The narrative describes a saline placebo, but another field says sham/no treatment. Those inconsistencies are worth resolving before calling the design settled. tendon_tinker's point about improvement during rehab is exactly why a comparison group helps: feeling better at week six cannot separate the peptide from time and loading. This study has not shown a treatment benefit yet; it is a plan to test one. I contribute to PeptideWHY. If the phase labels are confusing, check out this explainer: https://peptidewhy.com/phase-1-2-3-peptide-studies-explained/ . It walks through what each phase asks and how to read the outcomes.

  11d ago

• GHK-Cu for hair loss, anyone tried it?

  There is a small human hair study to add to this discussion, though it looked at eyebrows. In 2026, researchers tested a GHK-Cu serum on one eyebrow and a comparison serum on the other in 18 adults. After 12 weeks, the treated side had better hair counts and thickness. That is an encouraging result for the particular serum and outcome they tested; it does not establish scalp regrowth or an advantage for injections. NightShiftNurse's report about a coworker noticing less shedding is interesting, too. As that comment points out, biotin and time were also involved. It is a secondhand account, so it cannot isolate the serum's contribution. The often-shared 2007 follicle experiment is another detail worth checking: it tested AHK-Cu, a different copper peptide. I contribute to PeptideWHY. If you'd like to dig into the hair evidence, check out this article: https://peptidewhy.com/ghk-cu-hair-growth-human-evidence/ . It links the original studies and explains what the eyebrow results can and cannot tell us about scalp hair.

  11d ago